先進治療藥物（ATMP）CDMO市場規模、佔有率和成長分析：按治療方法、服務類型、應用、企業規模和地區分類－2026-2033年產業預測

2024 年全球先進治療藥物 CDMO 市值為 67.1 億美元，預計到 2033 年將從 2025 年的 79.8 億美元成長至 319.2 億美元，在預測期（2026-2033 年）內複合年成長率為 18.92%。

全球先進治療藥物（ATMP）合約開發和生產組織（CDMO）市場主要受細胞和基因治療產品線成長帶來的專業化生產能力需求的推動。這些CDMO在將複雜的生物製藥推向臨床應用的過程中發揮著至關重要的作用，需要獨立的無塵室環境和嚴格的品質保證流程。隨著基因療法獲準數量的增加，該產業正從小規模學術研究型GMP設施向大規模商業化組織核准，凸顯了擴大產能的必要性。這一趨勢推動了對創新製造技術和自動化的巨額投資，從而縮短了生產週期並提高了擴充性。人工智慧在生產流程中的應用進一步提高了效率，簡化了操作，並確保了高品質的結果，最終吸引了更多投資，並擴大了先進療法的地域覆蓋範圍。

全球先進治療藥物CDMO市場成長要素

隨著人們的關注點轉向個人化醫療和細胞療法，全球先進治療藥物CDMO市場對專業生產技術的需求日益成長。隨著研發人員轉向個人化治療方案，他們越來越依賴能夠管理複雜流程、生產客製化批次藥物以及處理敏感生物材料的外部合作夥伴。這種需求推動了CDMO產業對專業設施、專業技術人員和先進能力的投資。這些夥伴關係無需企業自行建設基礎設施即可獲得最尖端科技，從而加速專案進度並拓展先進治療藥物的商業性機會。

全球先進治療藥物CDMO市場的限制因素

由於各司法管轄區法規結構的嚴格性和不斷變化，全球先進治療藥物CDMO市場面臨嚴峻挑戰。這些法規帶來了沉重的合規負擔，導致CDMO及其客戶的專案週期延長，營運複雜性增加。滿足多樣化的監管要求需要先進的專業知識、詳盡的文件和嚴格的流程驗證，這可能會分散企業在創新和擴張方面的精力和資源。此外，新治療方法要求的不確定性導致投資謹慎，並使技術轉移複雜化，從而限制了能夠為先進治療方法開發商提供支援的供應商的選擇。因此，這種監管複雜性阻礙了市場成長，提高了准入門檻，延長了研發週期。

全球先進治療藥物CDMO市場趨勢

全球先進治療藥物合約研發生產力機構（CDMO）市場正呈現顯著的模組化生產趨勢。這一轉變的特點是引入了靈活的設施設計，能夠快速重新配置以適應各種細胞療法和基因療法。標準化的即插即用模組能夠實現快速的技術轉移和可擴展產能的部署，同時保持嚴格的品管。這種架構方法增強了對不斷變化的客戶需求的應對力，縮短了商業化時間，並促進了基於平台的思維模式，從而推動了可重複流程和可預測的專案進度。這使得企業能夠根據治療方法的演進和策略投資趨勢調整其產能。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球先進治療藥物（ATMP）CDMO市場規模：依治療類型分類

• 基因治療
  • 病毒載體
  • 非病毒載體
• 細胞療法
  • 自體療法
  • 順勢療法
• 組織工程產品
• 複雜 ATMP
• 其他

全球先進治療藥物（ATMP）CDMO市場規模：按服務類型分類

• 製程開發
• 分析與發展
• 臨床生產
• 商業生產
• 灌裝和包裝服務
• 其他

全球先進治療藥物（ATMP）CDMO市場規模：按應用領域分類

• 腫瘤學
• 罕見疾病
• 心血管疾病
• 神經系統疾病
• 其他

全球先進治療藥物（ATMP）CDMO市場規模：依業務規模分類

• 臨床量表
• 商業規模

全球先進治療藥物（ATMP）CDMO市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Lonza Group
• Catalent
• WuXi Advanced Therapies
• Thermo Fisher Scientific
• Charles River Laboratories
• Sartorius Stedim Biotech
• Boehringer Ingelheim
• AGC Biologics
• Merck
• Fujifilm Diosynth
• Cellares
• Resilience
• Oxford Biomedica
• Takara Bio
• Bio-Techne
• ElevateBio
• Bluebird Bio
• Legend Biotech
• Minaris Regenerative Medicine
• KBI Biopharma

結論與建議

Global Advanced Therapy Medicinal Products Cdmo Market size was valued at USD 6.71 Billion in 2024 and is poised to grow from USD 7.98 Billion in 2025 to USD 31.92 Billion by 2033, growing at a CAGR of 18.92% during the forecast period (2026-2033).

The global market for advanced therapy medicinal products contract development and manufacturing organizations (CDMOs) is significantly driven by the burgeoning demand for specialized manufacturing capabilities due to the rising cell and gene therapy pipelines. These CDMOs facilitate the translation of complex biologics into clinical applications, necessitating tailored cleanroom environments and stringent quality assurance protocols. The sector has transformed from small academic GMP setups to large-scale commercial entities, underscoring the essential need for capacity expansion amidst increasing approvals for gene therapies. This trend has spurred substantial investments in innovative manufacturing technologies and automation, reducing production cycle times while enhancing scalability. The integration of AI in manufacturing processes further amplifies efficiency, streamlining operations, and ensuring high-quality outputs, subsequently attracting more investment and geographic access to advanced therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Advanced Therapy Medicinal Products Cdmo market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Advanced Therapy Medicinal Products Cdmo Market Segments Analysis

Global advanced therapy medicinal products cdmo market is segmented by therapy type, service type, application, scale of operation and region. Based on therapy type, the market is segmented into Gene Therapy, Cell Therapy, Tissue Engineered Products, Combined ATMPs and Others. Based on service type, the market is segmented into Process Development, Analytical Development, Clinical Manufacturing, Commercial Manufacturing, Fill-Finish Services and Others. Based on application, the market is segmented into Oncology, Rare Diseases, Cardiovascular Diseases, Neurological Disorders and Others. Based on scale of operation, the market is segmented into Clinical Scale and Commercial Scale. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Advanced Therapy Medicinal Products Cdmo Market

The increasing focus on personalized and cell-based therapies is fueling the demand for specialized manufacturing expertise within the global Advanced Therapy Medicinal Products CDMO market. As developers shift towards individualized treatment approaches, there is a growing reliance on external partners capable of managing intricate processes, producing customized batches, and handling sensitive biological materials. This necessity drives investment in specialized facilities, skilled professionals, and advanced capabilities within the CDMO sector. By providing access to cutting-edge technologies without the need for in-house infrastructure, these partnerships facilitate the rapid advancement of programs and expand the commercial opportunities for advanced therapy medicinal products.

Restraints in the Global Advanced Therapy Medicinal Products Cdmo Market

The Global Advanced Therapy Medicinal Products CDMO market faces notable challenges due to stringent and constantly changing regulatory frameworks in various jurisdictions. These regulations impose significant compliance burdens, resulting in extended project timelines and heightened operational complexity for Contract Development and Manufacturing Organizations (CDMOs) and their clients. The necessity to meet diverse regulatory demands requires substantial expertise, extensive documentation, and rigorous process validation, which can divert attention and resources from innovations and expansion initiatives. Additionally, uncertainty surrounding requirements for new therapeutic modalities fosters cautious investment and complicates technology transfer, thereby limiting the pool of providers available to support advanced therapy developers. As a result, this regulatory complexity acts as a barrier to market growth, raising entry hurdles and prolonging development cycles.

Market Trends of the Global Advanced Therapy Medicinal Products Cdmo Market

The Global Advanced Therapy Medicinal Products CDMO market is experiencing a significant trend towards the adoption of modular manufacturing. This shift is characterized by the implementation of flexible facility designs that allow for rapid reconfiguration to accommodate a variety of cellular and gene therapies. Standardized, plug-and-play modules facilitate swift technology transfers and scalable capacity deployments while upholding stringent quality controls. Such an architectural approach enhances responsiveness to fluctuating client needs, reduces time to commercial readiness, and fosters a platform mindset that encourages repeatable processes and predictable project timelines, ultimately enabling firms to align their capacity with the evolving landscape of therapeutic modalities and strategic investments.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Advanced Therapy Medicinal Products CDMO Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Gene Therapy
  • Viral Vectors
  • Non-Viral Vectors
• Cell Therapy
  • Autologous Therapies
  • Allogeneic Therapies
• Tissue Engineered Products
• Combined ATMPs
• Others

Global Advanced Therapy Medicinal Products CDMO Market Size by Service Type & CAGR (2026-2033)

• Market Overview
• Process Development
• Analytical Development
• Clinical Manufacturing
• Commercial Manufacturing
• Fill-Finish Services
• Others

Global Advanced Therapy Medicinal Products CDMO Market Size by Application & CAGR (2026-2033)

• Market Overview
• Oncology
• Rare Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Others

Global Advanced Therapy Medicinal Products CDMO Market Size by Scale of Operation & CAGR (2026-2033)

• Market Overview
• Clinical Scale
• Commercial Scale

Global Advanced Therapy Medicinal Products CDMO Market Size & CAGR (2026-2033)

• North America (Therapy Type, Service Type, Application, Scale of Operation)
  • US
  • Canada
• Europe (Therapy Type, Service Type, Application, Scale of Operation)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Service Type, Application, Scale of Operation)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Service Type, Application, Scale of Operation)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Service Type, Application, Scale of Operation)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Lonza Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Advanced Therapies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius Stedim Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AGC Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Diosynth
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellares
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Resilience
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Biomedica
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ElevateBio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Legend Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Minaris Regenerative Medicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KBI Biopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations